IPO and L/S equity, 2015 Starmine top stock picker, Global Equity Research Ltd

Rickin Thakrar

IPO and L/S equity, 2015 Starmine top stock picker

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<a href="https://www.smartkarma.com/entities/qiagen-nv" target="_blank" data-smartkarma-citation="entities:26865:1" rel="noopener">QIAGEN NV (QIA GY)</a> shares have gone from strength to strength with the stock trading above terms and then receiving a bump bid late last week. <a href="https://www.smartkarma.com/entities/thermo-fisher-scientific-inc-49322cfa-b354-4c3d-ac3b-f4e91aead32b" target="_blank" data-smartkarma-citation="entities:26834:1" rel="noopener">Thermo Fisher (TMO UN)</a> raised its bid on Qiagen by 900 million euros (1bn USD) to 43 euros per share. This represents a c10% increase in the bid price. In addition, Thermo Fisher has reduced the minimum acceptance threshold to 66.67% of outstanding ordinary share capital from 75%, while extending the deal deadline by two weeks until August 10. Prominent hedge fund Davidson Kempner said it would still reject the offer and noted a price of between 48-52 euros would be appropriate. (Source: Reuters)  Indeed, Qiagen, a biotech company that makes products related to coronavirus testing, has seen a swelling of demand for its products and also recently upgraded its earnings forecasts. We give our updated view on Qiagen below the fold. Our previous positive research on the deal can be viewed here:<a href="https://www.smartkarma.com/insights/feedback-from-qiagen-ir-regarding-thermo-fisher-deal" target="_blank" data-smartkarma-citation="insights:37771" rel="noopener">Feedback from Qiagen IR Regarding Thermo Fisher Deal</a> <a href="https://www.smartkarma.com/insights/thermofisher-bids-for-qiagen-a-covid-19-pivot" target="_blank" data-smartkarma-citation="insights:37556" rel="noopener">Thermofisher Bids for Qiagen - A COVID-19 Pivot?</a>

QIAGEN NV (QIA GY) shares have gone from strength to strength with the stock trading above terms and then receiving a bump bid late last week. Thermo Fisher (TMO UN) raised its bid on Qiagen by 900 million euros (1bn USD) to 43 euros per share. This represents a c10% increase in the bid price. In addition, Thermo Fisher has reduced the minimum acceptance threshold to 66.67% of outstanding ordinary share capital from 75%, while extending the deal deadline by two weeks until August 10. Prominent hedge fund Davidson Kempner said it would still reject the offer and noted a price of between 48-52 euros would be appropriate. (Source: Reuters)  Indeed, Qiagen, a biotech company that makes products related to coronavirus testing, has seen a swelling of demand for its products and also recently upgraded its earnings forecasts. We give our updated view on Qiagen below the fold. Our previous positive research on the deal can be viewed here:Feedback from Qiagen IR Regarding Thermo Fisher Deal Thermofisher Bids for Qiagen - A COVID-19 Pivot? 

Qiagen/Thermo Fisher: Qiagen Gets a Bump – Is It Enough to Satisfy Shareholders?

United States

Bio-Techne Corp develops, manufactures and sells biotechnology products and clinical diagnostic controls. The Company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bio Techne Corp (TECH US)

Qiagen/Thermo Fisher: Qiagen Gets a Bump – Is It Enough to Satisfy Shareholders?

QIAGEN NV (QIA GY) shares have gone from strength to strength with the stock trading above terms and then receiving a bump bid late last week....

Rickin Thakrar

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)